InsiderPulse
Dashboard

ZLAB

Zai Lab Limited

Health CareRussell 2000

Zai Lab Limited insider trading

Zai Lab Limited files with the SEC as a Pharmaceutical Preparations company headquartered in Shanghai. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent ZLAB insider transactions

7 insiders traded ZLAB on the open market between Apr 06, 2026 and Aug 19, 2026 — 1 purchase worth $33.1K, 19 sales worth $5.3M, of which 10 were pre-scheduled under a 10b5-1 plan.

Bought
$33.1K
Sold
$5.3M

10 of 19 on a 10b5-1 plan

Net
−$5.3M
Insiders
7

Open-market purchases (code P) and sales (code S) from Zai Lab Limited's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every ZLAB Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

ZLAB insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 9 insiders traded ZLAB on the open market: 2 purchases worth $321.8K and 100 sales worth $37.4M, 54 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 2 purchases ($321.8K) and 48 sales ($18.4M), by 7 insiders.

QuarterBoughtSold
Q2 2026—−$5.6M20 sales · 7 on a plan
Q1 2026+$32.7K1 buy−$4.5M12 sales · 8 on a plan
Q4 2025—−$641.8K5 sales · 2 on a plan
Q3 2025+$289.1K1 buy−$7.7M11 sales · 8 on a plan
Q2 2025—−$10.2M25 sales · 10 on a plan
Q1 2025—−$7.8M15 sales · all on a plan
Q4 2024—−$212K3 sales
Q3 2024—−$647.2K9 sales · 4 on a plan
Largest purchase
+$289.1K of ZLAB by Smiley Joshua L (President and Chief Operating Officer) on Sep 10, 2025.
Largest sale
−$1.7M of ZLAB by Du Ying (Chairperson & CEO · Director) on Aug 08, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Du Ying

    Chairperson & CEO · Director

    −$428.5K

    Jun 26, 2026

    24,543 sh · $17.46

  • Edmondson Frazor Titus III

    Chief Legal Officer

    −$71.6K

    Jun 26, 2026

    4,103 sh · $17.46

  • Chen Yajing

    Chief Financial Officer

    −$39.5K

    Jun 26, 2026

    2,264 sh · $17.46

  • Du Ying10b5-1

    Chairperson & CEO · Director

    −$950K

    May 18, 2026

    50,000 sh · $19.00

  • Du Ying10b5-1

    Chairperson & CEO · Director

    −$1M

    May 15, 2026

    50,000 sh · $20.74

  • Du Ying10b5-1

    Chairperson & CEO · Director

    −$1M

    May 14, 2026

    50,000 sh · $20.09

  • Du Ying10b5-1

    Chairperson & CEO · Director

    −$682.8K

    May 13, 2026

    33,769 sh · $20.22

  • Du Ying10b5-1

    Chairperson & CEO · Director

    −$315.5K

    May 13, 2026

    16,231 sh · $19.44

  • Smiley Joshua L

    President and Chief Operating Officer

    −$61.7K

    Apr 06, 2026

    3,017 sh · $20.45

  • Amado Rafael

    President, Head of Global Oncology Research and Development

    −$56K

    Apr 06, 2026

    2,739 sh · $20.45

  • Du Ying

    Chairperson & CEO · Director

    −$54.3K

    Apr 06, 2026

    2,653 sh · $20.45

  • Edmondson Frazor Titus III

    Chief Legal Officer

    −$25K

    Apr 06, 2026

    1,224 sh · $20.45

  • Chen Yajing

    Chief Financial Officer

    −$17.4K

    Apr 06, 2026

    853 sh · $20.45

  • Amado Rafael

    President, Head of Global Oncology Research and Development

    −$202.1K

    Apr 02, 2026

    9,910 sh · $20.39

  • Smiley Joshua L

    President and Chief Operating Officer

    −$196K

    Apr 02, 2026

    9,614 sh · $20.39

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Zai Lab Limited company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Shanghai
Incorporated in
E9
Listed on
Nasdaq
SEC Central Index Key
0001704292

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought ZLAB

What the stock actually did in the 90 days following each open-market purchase

Don't check ZLAB — let it ping you

Get told the moment an insider moves on ZLAB

Pro watches Zai Lab Limited for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add ZLAB to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track ZLAB on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read ZLAB insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

ATTODNTHUTHRCORTHRMYSUPNOMCLHQYDOCSOSCRALHCASTH
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are ZLAB insiders buying or selling?
Between Apr 06, 2026 and Aug 19, 2026, 7 Zai Lab Limited insiders made 1 open-market purchase worth $33.1K and 19 sales worth $5.3M, a net sale of $5.3M. 10 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much ZLAB stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 9 Zai Lab Limited insiders made 2 open-market purchases worth $321.8K and 100 sales worth $37.4M. 54 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 2 purchases ($321.8K) and 48 sales ($18.4M). The largest purchase was Smiley Joshua L buying $289.1K on Sep 10, 2025. The largest sale was Du Ying selling $1.7M on Aug 08, 2025.
What was the largest recent ZLAB insider trade?
Du Ying (Chairperson & CEO · Director) sold $1M of ZLAB stock on May 15, 2026 at about $20.74 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy ZLAB shares?
The most recent open-market purchase on file is Gaynor Richard (Director) buying $33.1K on Jul 01, 2026.
Where does ZLAB insider trading data come from?
From the Form 4 filings Zai Lab Limited's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.